These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 8635360)

  • 1. Is there a standard treatment for locally advanced non-small cell lung cancer?
    Buccheri G
    Chest; 1996 Apr; 109(4):864-6. PubMed ID: 8635360
    [No Abstract]   [Full Text] [Related]  

  • 2. Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer.
    Toschi L; Cappuzzo F; Jänne PA
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix150-5. PubMed ID: 17631569
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined modality therapy for early stage operable and locally advanced potentially resectable non-small cell lung carcinoma.
    Clark JI; Albain KS
    Cancer Treat Res; 2001; 105():149-70. PubMed ID: 11224986
    [No Abstract]   [Full Text] [Related]  

  • 4. The Optimal Local Treatment of Stage IIIA-N2 NSCLC: Is the Issue Finally Settled?
    De Ruysscher D; Vansteenkiste J; Belderbos J; Decaluwé H; Dingemans AM
    J Thorac Oncol; 2016 Mar; 11(3):284-6. PubMed ID: 26922920
    [No Abstract]   [Full Text] [Related]  

  • 5. [Management of non-small-cell lung carcinoma (NSCLC) of stage III B].
    Koukourakis M
    Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S33-6. PubMed ID: 11924241
    [No Abstract]   [Full Text] [Related]  

  • 6. [Combined-modality therapy for lung cancer].
    Miura S; Yamamoto N
    Nihon Rinsho; 2010 Jun; 68(6):1121-8. PubMed ID: 20535966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non small-cell lung cancer.
    Leo F; De Pas T; Catalano G; Piperno G; Curigliano G; Solli P; Veronesi G; Petrella F; Spaggiari L
    J Natl Cancer Inst; 2007 Aug; 99(15):1210; author reply 1210-1. PubMed ID: 17652281
    [No Abstract]   [Full Text] [Related]  

  • 8. [Can positron-emission tomography modify the management of non-small-cell lung cancer?].
    Ninane V
    Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S5-7. PubMed ID: 16719146
    [No Abstract]   [Full Text] [Related]  

  • 9. Combined-modality treatment of locally advanced non-small cell lung cancer: incorporation of novel chemotherapeutic agents.
    Belani CP; Ramanathan RK
    Chest; 1998 Jan; 113(1 Suppl):53S-60S. PubMed ID: 9438691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of stage IIIA non-small cell lung cancer.
    Robinson LA; Wagner H; Ruckdeschel JC;
    Chest; 2003 Jan; 123(1 Suppl):202S-220S. PubMed ID: 12527580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and management of early lung cancer.
    Park BJ; Altorki NK
    Surg Clin North Am; 2002 Jun; 82(3):457-76, v. PubMed ID: 12371580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of adjuvant chemotherapy in the treatment of early stage NSCLC after radical surgery].
    De Marinis F; De Petris L
    Suppl Tumori; 2004; 3(4):S50-1. PubMed ID: 15206212
    [No Abstract]   [Full Text] [Related]  

  • 13. [Neoadjuvant Radiochemotherapy Followed by Curative Resection in Patients with Advanced Non-Small Cell Lung Cancer in Stage IIIA/IIIB: Prognostic Factors and Results].
    Schreiner W; Dudek W; Lettmaier S; Gavrychenkova S; Rieker R; Fietkau R; Sirbu H
    Zentralbl Chir; 2016 Jun; 141(3):323-9. PubMed ID: 27035568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung cancer highlights.
    Lynch TJ
    Oncologist; 1999; 4(4):279-86. PubMed ID: 10476538
    [No Abstract]   [Full Text] [Related]  

  • 15. What is the optimal treatment of stage IIIA-N2 non-small-cell lung cancer after EORTC 08941?
    Van Meerbeeck JP; De Pauw R; Tournoy K
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):199-206. PubMed ID: 18279061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the routine use of trimodality therapy for selected patients with non-small cell lung cancer supported by long-term clinical outcomes?
    Dickhoff C; Hartemink KJ; Kooij J; van de Ven PM; Paul MA; Smit EF; Dahele M
    Ann Oncol; 2017 Jan; 28(1):185. PubMed ID: 27687305
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic implications of molecular imaging with PET in the combined modality treatment of lung cancer.
    van Loon J; van Baardwijk A; Boersma L; Ollers M; Lambin P; De Ruysscher D
    Cancer Treat Rev; 2011 Aug; 37(5):331-43. PubMed ID: 21320756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined modality therapy of non-small cell lung cancers.
    Juretic A; Sobat H; Samija M
    Ann Oncol; 1999; 10 Suppl 6():93-8. PubMed ID: 10676559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [What's new in lung cancer].
    Letonturier P
    Presse Med; 2007 Mar; 36(3 Pt 1):441-3. PubMed ID: 17436450
    [No Abstract]   [Full Text] [Related]  

  • 20. [Locally advanced and metastatic non-small-cell lung cancer: towards a new optimal therapeutic strategy].
    Fournel P
    Rev Pneumol Clin; 2004 Jun; 60 Spec no 2():2S8-15. PubMed ID: 15211226
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.